資源描述：
《射頻和自體腫瘤疫苗聯(lián)合治療肝癌臨床研究》由會員上傳分享，免費在線閱讀，更多相關(guān)內(nèi)容在學術(shù)論文-天天文庫。
1、射頻和自體腫瘤疫苗聯(lián)合治療肝癌臨床研究作者：李榮梅方雄白瑞球劉寧江高焱明鞏平【摘要】目的：探討射頻（RF）和新城雞瘟病毒（NDV）修飾自體腫瘤疫苗（ATV）聯(lián)合治療肝癌效果。方法：治療組28例進行RF聯(lián)合ATVNDV治療，對照組22例進行RF治療。RF共治療50例75個瘤體，其中3個瘤體8例，2個瘤體9例。術(shù)中切取腫瘤組織，進行免疫測定、病理檢查，治療組加作ATVNDV制備。根據(jù)瘤體大小設計射頻治療靶點，實施治療。結(jié)果：RF治療15d后75個瘤體57個完全壞死，12瘤體僅部分壞死，6例囊性變。兩組治
2、療前AFP升高者治療后降至正常。治療組治療后2月CD4+降低、NK、CD3+、CD4+/CD8+升高，生存率1、3、5年分別為72.2%、50.1%、40.4%，對照組為60.5%、43.6%、29.8%。結(jié)論：RF聯(lián)合ATVNDV治療肝癌瘤體縮小、AFP下降、免疫功能提高均較單純RF治療快，生存率提高，可能與ATVNDV應用延遲腫瘤復發(fā)有關(guān)?！娟P(guān)鍵詞】肝腫瘤・射頻・癌癥疫苗Theclinicalstudyonhypatocellularcarcinomatreatmen
3、twithradiofrequencycombinedwithautologoustumorvaccinemodifiedNewcastledisease8【ABSTRACT】Objective:Tocomparethetherapeuticefficacyofradiofrequnecy(RF)combinedwithAutologousTumorVaccinemodifiedbyNewcastieDiseas(ATVNDV)onthehepatocarcinomar.Methods:50case
4、sofpatientswithhepatocarcinomatreatedwiththeprocedureinourhospitalsince1999werestudiedAccordingtothehospitalizationorder,28caseswhosehospitalizationordernumberisoddreceivedRFcombinedwithATVNDV,22caseswhosehospitalizationordernumberiseventreatedwithRFon
5、ly;Therewere75tumorbodiestreated.Therewere8caseswith3tumorbodies,9caseswithtumorbodies.Intheoperation,wecutenoughtumortissueforimmunoassayandpathologicalexamination.WeproducedATVNDVadditionallyinthetherapygroup,designedtheRFtherapeutictargetaccordingto
6、thetumorbodysize,thenexecutivedtreatment.Results:After15daysofRFtherapy,57tumorbodieswerecompletelynecrotic,12bodieswithpartialnecrosis,6tumorbodieswerecysticdegeneration.Thehighalphafetoprotein(AFP)levelsdecreasedtonormalinbothgroups.After2months,thel
7、evelsofNK、CD3+、CD4+/CD8+increasedwhileCD4+leveldecreasedinthetherapygroup1,3,5yearsurvivalratewere72.3%,50.1%,40.4%,respectively,inthecombinedtherapeuticgroupand60.5%,43.6%,29.8%,respectively,inthe8controlgroup.Conclusion:ComparedwiththeonlyRFtreatment
8、group,thesizeofthehepatocarcinomatumorbodydiminuted,thelevelofAFPdecreaseandtheimmunologicalfunctionimproveintheRFcombinedwithATVNDVgroupisfaster.ThesurvivalrateintheRFcombinedwithATVNDVgroupislongerthanthatintheonlyRFtherapygroup,which
